An interventional study of Nicotine and Vaporizer Device in Nicotine Dependence, sponsored by Roswell Park Cancer Institute. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-31.
Sponsored by Roswell Park Cancer Institute · Not applicable, Interventional, and Prevention
This trial studies activity of time (pharmacokinetics), subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or e-liquids. This study aims to determine and compare the levels of nicotine delivered to the bloodstream from nicotine salt and free-base nicotine e-liquid solutions.
PRIMARY OBJECTIVES:
I. To determine the effect of nicotine salt (nicotine benzoate) and free-base nicotine in different flavored e-liquid solutions on puffing behaviors and systemic exposure to nicotine from electronic nicotine delivery systems (ENDS) by:
Ia. Assessing short-term effects on nicotine cravings, withdrawal, and satisfaction from single use of ENDS refilled with flavored nicotine salt or flavored free-base nicotine solutions with two different flavors (tobacco or unflavored) in current daily ENDS users following an overnight fast.
Ib. Comparing users' perceptions and preferences towards inhaling vapors containing nicotine salt (nicotine benzoate) or freebase nicotine with two different flavors (tobacco and unflavored) versus their regular brand.
II. This project provides important information on whether the pharmacokinetics of nicotine delivery differ between salt and free-base forms of e-liquid of equivalent nominal concentration using the same device, and whether the previously observed effects of flavors on subjective effects differ between salt and free-base forms.
III. Determine whether maximum concentration of nicotine in plasma (Cmax) or time to maximum concentration (Tmax) differ between free-base and salt-based versions of the same liquid, controlling for flavoring and nominal nicotine concentration [main effect of salt].
IV. Determine whether the effect of flavoring on subjective effects (e.g., harshness, liking) differs between matched free-base and salt-based e-liquids [flavor X salt interaction].
EXPLORATORY OBJECTIVE:
I. Examine effects of salt and flavoring on abuse liability using the Experimental Tobacco Marketplace (ETM).
OUTLINE:
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine electronic (e)-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
968 studies on the registry are indexed under Tobacco Use Disorder; 126 are open to participants now.
This study's enrollment of 15 is below the median of 89 across 851 interventional studies indexed under Tobacco Use Disorder.
Browse Tobacco Use Disorder studies →Roswell Park Cancer Institute is the lead sponsor of 412 studies on the registry; 62 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 21 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Current daily ENDS user as determined by
Exclusion Criteria:
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Device: Vaporizer Device · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Free-Low Nicotine Tobacco Flavored (Product C)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours , 5-7 days apart. They are randomized to take 20 puffs over 10 minutes (1 puff every 30 seconds) of vaporized filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored or salt based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Drug: Nicotine · Device: Vaporizer Device · Drug: Salt-HIgh Nicotine Unflavored (Product B) · Drug: Free-Low Nicotine Tobacco Flavored (Product C) · Drug: Salt-High Nicotine Tobacco Flavored (Product D)
Vape Free-Low nicotine unflavored
Also known as: Free-Low Nicotine Unflavored (Product A), NIC
Take puffs from vaporizer filled with different flavors
Also known as: Vaporizer
Vape Salt-High nicotine unflavored
Vape Free-Low Nicotine Tobacco
Vape Salt-High Tobacco
Maximum Concentration of Nicotine in Plasma (Cmax)
The maximum nicotine concentration in blood plasma
Time frame: Samples were taken at minutes 0, then they started puffing and samples were taken 2, 4, 5, 6, 8, 10 minutes during puffing. Then, samples were taken at times 13, 15, 20, 30, and 120 minutes post puffing. The last dose occurred at week 4.
Area Under the Concentration-time Curve (AUC)
Area under the plasma nicotine concentration over time curve
Time frame: Samples were taken at minutes 0, then they started puffing and samples were taken 2, 4, 5, 6, 8, 10 minutes during puffing. Then, samples were taken at times 13, 15, 20, 30, and 120 minutes post puffing. The last dose occurred at week 4.
Time to Maximum Concentration
Time to maximum nicotine concentration in the blood plasma
Time frame: Samples were taken at minutes 0, then they started puffing and samples were taken 2, 4, 5, 6, 8, 10 minutes during puffing. Then, samples were taken at times 13, 15, 20, 30, and 120 minutes post puffing. The last dose occurred at week 4.
Perceived Harshness of Experimental Product Sampled
Subjective Measure of Perceived Harshness (Likert, 1-5: 1 = best outcome, 5 = worst outcome).
Time frame: 1 minute post puffing for 4 weeks
Perceived Satisfaction of Experimental Product Sampled
Nicotine Solution Rating Scale that orders each of the four products from 1 to 4, with 1 being least satisfying and 4 being most satisfying. Mean rank is provided with a possible score of 1 through 4.
Time frame: 120 minutes after session start on last session (session 4)
Perceived Liking of Experimental Product Sampled
Drug Effects Questionnaire Item #1 - perceived liking of the experimental product assessed by the question, "Do you like any of the effects you are feeling right now?" on a Likert scale from 0 (not at all) to 100 (extremely), with lower scores representing less liking of the experimental product. Mean is provided with possible scores between 0 and 100.
Time frame: 1 minute post puffing for 4 weeks
Minnesota Nicotine Withdrawal Scale Change (Change From Pre- to Post-)
Minnesota Nicotine Withdrawal Scale Change Minnesota Nicotine Withdrawal scale measures 8 facets of withdrawal and results in a total score. We use change from 5 minutes Pre-puffing to 3 minutes post puffing session. Individual questions are scored 0 (none/better) to 4 (severe/worse). And then the scores are totaled. Positive change score = more withdrawal symptoms. Change score can range from -32 to 36). Positive change score = worse withdrawal symptoms Individual questions are scored 0 (none/better) to 4 (severe/worse). And then the scores are totaled.
Time frame: 5 minutes pre puffing and 3 minutes post puffing for 4 weeks
Intensity of Demand or Estimated Milligrams E-cigarettes Purchased at Free Cost for Each Device Sampled
Demand intensity is a behavioral economic estimated measure of consumption at zero cost in a experimental marketplace focused on purchasing of tobacco and nicotine products over increasing price of one product while others stay the same price. Participants were asked to purchase tobacco products (12 options) for one week's use. At each of the four sessions, participants experienced a marketplace with e-cigarette liquid prices of $1.63, $3.25, $6.50, and $13.00, while the prices of the other 11 tobacco products remained the same. Units purchased are transformed into mg of nicotine and nonlinear regression is used to estimate the purchasing when e-cigarettes are free/demand intensity, which is reported here. Higher scores indicate more mg of nicotine from e-cigarettes were purchased
Time frame: 60 minutes post puffing for 4 weeks
Elasticity of Demand or Sensitivity to Price for Each Device Sampled
Demand elasticity , or sensitivity to price, is a behavioral economic measure of of the rate of purchasing decline over increasing cost for e-cigarettes. At each of the four sessions, participants experienced a marketplace with e-cigarette liquid prices of $1.63, $3.25, $6.50, and $13.00, while the prices of the other 11 tobacco products remained the same. Units purchased are transformed into mg of nicotine and nonlinear regression is used to estimate the purchasing when e-cigarettes are free/demand intensity, which is reported here. Higher scores indicate more sensitivity to price, also called inelastic demand.
Time frame: 60 minutes post puffing for 4 weeks
Substitution Levels of Alternative Tobacco Products
Substitution is the slope of the line regressing consumption of the substitute product onto the price of cigarettes (cross-price elasticity). A positive coefficient indicates substitution (use of the substitute increases with increasing cigarette price). A negative value indicates complementarity (use of the substitute declines with increasing cigarette price). A value of 0 indicates no relationship.
Time frame: 120 minutes post puffing for 4 weeks
| Milestone | Product Sequence D | Product Sequence A then B then C | Product sequence B then C then A then D | Product sequence D then B then A then C | Product sequence C then D then B then A | Product sequence A then C | Product sequence D then C then B then A | Product sequence A then D then B then C | Product sequence D then A then C then B | Product sequence C then D then A then B | Product sequence A then C then D then B | Product Sequence A then B then D then C | Product sequence B then A then D thn C | Product sequence B then D then C then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The maximum nicotine concentration in blood plasma
| ng/mL | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Maximum Concentration of Nicotine in Plasma (Cmax) | 5.7 ± 0.8 | 11.8 ± 3.3 | 6.7 ± 1.3 | 8.1 ± 1.7 |
Area under the plasma nicotine concentration over time curve
| ng*min/mL | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) | 128.8 ± 40.8 | 295.6 ± 126.7 | 177.3 ± 51.7 | 199.7 ± 71.7 |
Time to maximum nicotine concentration in the blood plasma
| minutes | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Time to Maximum Concentration | 11.5 ± 1.6 | 9.8 ± 1.5 | 11.7 ± 1.5 | 8.6 ± 1.3 |
Subjective Measure of Perceived Harshness (Likert, 1-5: 1 = best outcome, 5 = worst outcome).
| score on a scale | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Perceived Harshness of Experimental Product Sampled | 4.85 ± 0.1 | 2.92 ± 0.4 | 4.62 ± 0.1 | 3.08 ± 0.4 |
Nicotine Solution Rating Scale that orders each of the four products from 1 to 4, with 1 being least satisfying and 4 being most satisfying. Mean rank is provided with a possible score of 1 through 4.
| score on a scale | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Perceived Satisfaction of Experimental Product Sampled | 3.08 ± 0.3 | 3.75 ± 0.4 | 3.77 ± 0.4 | 4.23 ± 0.3 |
Drug Effects Questionnaire Item #1 - perceived liking of the experimental product assessed by the question, "Do you like any of the effects you are feeling right now?" on a Likert scale from 0 (not at all) to 100 (extremely), with lower scores representing less liking of the experimental product. Mean is provided with possible scores between 0 and 100.
| score on a scale | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Perceived Liking of Experimental Product Sampled | 45.9 ± 5.2 | 55.2 ± 4.0 | 46.5 ± 6.0 | 52.5 ± 5.4 |
Minnesota Nicotine Withdrawal Scale Change Minnesota Nicotine Withdrawal scale measures 8 facets of withdrawal and results in a total score. We use change from 5 minutes Pre-puffing to 3 minutes post puffing session. Individual questions are scored 0 (none/better) to 4 (severe/worse). And then the scores are totaled. Positive change score = more withdrawal symptoms. Change score can range from -32 to 36). Positive change score = worse withdrawal symptoms Individual questions are scored 0 (none/better) to 4 (severe/worse). And then the scores are totaled.
| score on a scale | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Minnesota Nicotine Withdrawal Scale Change (Change From Pre- to Post-) | 0.5 ± 0.7 | 0.7 ± 0.7 | 1.5 ± 0.5 | -0.5 ± 0.7 |
Demand intensity is a behavioral economic estimated measure of consumption at zero cost in a experimental marketplace focused on purchasing of tobacco and nicotine products over increasing price of one product while others stay the same price. Participants were asked to purchase tobacco products (12 options) for one week's use. At each of the four sessions, participants experienced a marketplace with e-cigarette liquid prices of $1.63, $3.25, $6.50, and $13.00, while the prices of the other 11 tobacco products remained the same. Units purchased are transformed into mg of nicotine and nonlinear regression is used to estimate the purchasing when e-cigarettes are free/demand intensity, which is reported here. Higher scores indicate more mg of nicotine from e-cigarettes were purchased
| mg of nicotine | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Intensity of Demand or Estimated Milligrams E-cigarettes Purchased at Free Cost for Each Device Sampled | 908.3 (425.1 to 2022) | 1142 (539.2 to 2926) | 785.5 (416.1 to 1521) | 985.8 (475.7 to 2416) |
Demand elasticity , or sensitivity to price, is a behavioral economic measure of of the rate of purchasing decline over increasing cost for e-cigarettes. At each of the four sessions, participants experienced a marketplace with e-cigarette liquid prices of $1.63, $3.25, $6.50, and $13.00, while the prices of the other 11 tobacco products remained the same. Units purchased are transformed into mg of nicotine and nonlinear regression is used to estimate the purchasing when e-cigarettes are free/demand intensity, which is reported here. Higher scores indicate more sensitivity to price, also called inelastic demand.
| mg nicotine per dollar | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| Elasticity of Demand or Sensitivity to Price for Each Device Sampled | 0.0005 (.0002 to .0007) | 0.0004 (.0002 to .0006) | 0.0004 (.0002 to .0006) | 0.0005 (.0003 to .0007) |
Substitution is the slope of the line regressing consumption of the substitute product onto the price of cigarettes (cross-price elasticity). A positive coefficient indicates substitution (use of the substitute increases with increasing cigarette price). A negative value indicates complementarity (use of the substitute declines with increasing cigarette price). A value of 0 indicates no relationship.
| mg nicotine per dollar | A: Unflavored Free-based Nicotine Form | B: Unflavored Salt-based Nicotine Form | C: Tobacco Flavor Free-based Nicotine Form | D: Tobacco Flavor Salt-based Nicotine Form |
|---|---|---|---|---|
| JUUL Virginia Tobacco | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 7.377 (-0.5177 to 15.27) |
| JUUL Classic Tobacco | -0.000000000000 (-87.64 to 87.64) | 8.167 (-69.45 to 85.78) | 2.554 (-81.9 to 87.01) | -4.175 (-95.61 to 87.26) |
| JUUL Menthol | 15.54 (-38.02 to 69.11) | 17.31 (-36.31 to 70.93) | 14.75 (-32.1 to 61.61) | 18.28 (-26.91 to 63.47) |
| Revel Dark Mint | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Revel Mint | 4.232 (-1.547 to 10.01) | 0.2371 (-2.216 to 2.69) | 4.663 (-0.6079 to 9.935) | 0.2371 (-2.216 to 2.69) |
| Marlboro Reds | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Marlboro Menthols | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Camel Snus Mellow | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Camel Snus Frost | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| IQOS Menthol | 4.86 (0.398 to 9.359) | 4.389 (1.230 to 7.548) | 4.432 (-0.622 to 9.485) | 2.43 (-0.9026 to 5.762) |
| IQOS Tobacco | 0 (0 to 0) | 0.2552 (-2.385 to 2.895) | 2.382 (-0.1672 to 4.931) | 1.813 (-2637 to 6.262) |
Collected over 2 year and 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Unflavored Free-based Nicotine Form | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| B: Unflavored Salt-based Nicotine Form | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| C: Tobacco Flavor Free-based Nicotine Form | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| D: Tobacco Flavor Salt-based Nicotine Form | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
All treated and eligible patients
| Age, Continuous(years) | Product Sequence D | Product Sequence A Then B Then C | Product Sequence B Then C Then A Then D | Product Sequence D Then B Then A Then C | Product Sequence C Then D Then B Then A | Product Sequence A Then C | Product Sequence D Then C Then B Then A | Product Sequence A Then D Then B Then C | Product Sequence D Then A Then C Then B | Product Sequence C Then D Then A Then B | Product Sequence A Then C Then D Then B | Product Sequence A Then B Then D Then C | Product Sequence B Then A Then D Thn C | Product Sequence B Then D Then C Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 26 ± 2.8 | 24 ± na | 55 ± na | 37 ± na | 21 ± na | 21 ± na | 24 ± na | 23 ± na | 29 ± na | 26 ± na | 22 ± na | 32 ± na | 33 ± na | 32 ± na | 28.7 ± 8.7 |
| Sex: Female, Male(Participants) | Product Sequence D | Product Sequence A Then B Then C | Product Sequence B Then C Then A Then D | Product Sequence D Then B Then A Then C | Product Sequence C Then D Then B Then A | Product Sequence A Then C | Product Sequence D Then C Then B Then A | Product Sequence A Then D Then B Then C | Product Sequence D Then A Then C Then B | Product Sequence C Then D Then A Then B | Product Sequence A Then C Then D Then B | Product Sequence A Then B Then D Then C | Product Sequence B Then A Then D Thn C | Product Sequence B Then D Then C Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 5 |
| Male | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Product Sequence D | Product Sequence A Then B Then C | Product Sequence B Then C Then A Then D | Product Sequence D Then B Then A Then C | Product Sequence C Then D Then B Then A | Product Sequence A Then C | Product Sequence D Then C Then B Then A | Product Sequence A Then D Then B Then C | Product Sequence D Then A Then C Then B | Product Sequence C Then D Then A Then B | Product Sequence A Then C Then D Then B | Product Sequence A Then B Then D Then C | Product Sequence B Then A Then D Thn C | Product Sequence B Then D Then C Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Roswell Park Cancer Institute